Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

S 64315

Next Previous
Drug Profile

S 64315

Alternative Names: MIK-665; S-64315

Latest Information Update: 05 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Servier; Vernalis
  • Developer ADIR; IRIS; Novartis; Servier; Vernalis
  • Class Antineoplastics; Small molecules
  • Mechanism of Action MCL1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia; Breast cancer
  • No development reported Lymphoma; Multiple myeloma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma

Most Recent Events

  • 07 Dec 2024 Pharmacodynamics data from a preclinical study in Acute myeloid leukemia presented at 66th American Society of Hematology Annual Meeting and Exposition 2024 (ASH-Hem-2024)
  • 28 Sep 2024 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Combination therapy, Second-line therapy or greater) in Belgium (IV, Infusion)
  • 28 Sep 2024 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Combination therapy, Second-line therapy or greater) in Finland (IV, Infusion)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top